News

3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July
Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer.
American Council on Science and Health6hOpinion
Dangerous Gamble: U.S. Abandons Bird Flu Vaccine Preparedness
The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
FDA vaccine official restricted COVID vaccine approvals against agency advice
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines ...
Top FDA vaccine official rejected broad use of Covid-19 shots, documents show
The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons
Pfizer exec Philip Dormitzer amid claims the COVID-19 vaccine announcement was delayed to avoid influencing the 2020 election ...
We've Lowered Our Moat Rating for Pfizer to Narrow, Driven by Portfolio Setbacks and Policy Risk
We view Pfizer’s dividends and share repurchase levels as reasonable. Pfizer has generally targeted close to a 50% payout in dividends as a percentage of normalized earnings, which seems about right ...
Republicans subpoena former Pfizer exec over timing of COVID vaccine clinical tests
The House Judiciary Committee subpoenaed a former Pfizer executive who allegedly claimed senior members of the company ...
The Lancet2d
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study - The Lancet
In a pivotal randomised controlled trial, the BNT162b2 mRNA vaccine (tozinameran, Pfizer–BioNTech) showed 95% or greater efficacy against symptomatic and severe COVID-19 disease due to SARS-CoV-2. 1 ...